Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular diastolic dysfunction: risks, identification, and treatment.

Robert E Lamb1, Deborah King

  • 1Medical Affairs, AstraZeneca LP, 1800 Concord Pike, Wilmington, DE 19850, USA. robert.lamb@astrazeneca.com

Progress in Cardiovascular Nursing
|March 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Searching for immune correlates in Lassa vaccine development - workshop report.

NPJ vaccines·2026
Same author

Assessing for neonatal jaundice in the community: an integrative systematic review.

Midwifery·2026
Same author

Economic cost of strategic implementation approaches to increase uptake of digital therapeutics for substance use disorders in a large integrated health system.

PLOS digital health·2026
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.

The Lancet. Microbe·2025

Untreated cardiovascular risks like hypertension and diabetes can lead to chronic heart failure. Emerging clinical evidence supports effective treatments for heart failure with preserved systolic function (left ventricular diastolic dysfunction).

Area of Science:

  • Cardiology
  • Heart Failure Research

Background:

  • Cardiovascular diseases (hypertension, diabetes, myocardial infarction) untreated increase chronic heart failure risk.
  • Chronic heart failure with preserved systolic function (left ventricular diastolic dysfunction) lacks extensive clinical trial evidence compared to systolic dysfunction.
  • Treatment for diastolic dysfunction has historically relied on understanding pathophysiology and patient symptoms.

Purpose of the Study:

  • To review risks, identification, and therapeutic rationale for left ventricular diastolic dysfunction.
  • To discuss emerging clinical evidence supporting treatments for diastolic dysfunction.
  • To analyze implications from ongoing and completed trials like CHARM-Preserved and DIG.

Main Methods:

  • Review of existing literature and clinical trial data.

Related Experiment Videos

  • Analysis of risk factors and diagnostic approaches for diastolic dysfunction.
  • Evaluation of therapeutic strategies and their supporting evidence.

    • Main Results:

    • Accumulating clinical evidence from trials like CHARM-Preserved and DIG supports effective treatments for diastolic dysfunction.
    • Ongoing trials are expected to provide further insights into managing this condition.
    • Understanding pathophysiology and patient presentation remains crucial for treatment decisions.

    Conclusions:

    • Effective treatments for left ventricular diastolic dysfunction are becoming more defined.
    • Clinical trial results are crucial for evidence-based management of diastolic dysfunction.
    • Further research and ongoing trials will refine therapeutic choices for heart failure with preserved systolic function.